Guardians Against Humanity’s Greatest Health Threats
Enhancing Today’s Therapies.
Protecting Tomorrow’s Health.
Cerberus Biosciences is a therapeutics company pioneering artificial nucleoside technology to address three of the world’s most urgent health threats: drug-resistant infections, hard-to-treat cancers, and viral diseases. Our innovative platform enhances—not replaces—existing therapies, offering a scalable, cost-effective, and clinically validated solution to major unmet medical needs.
A Platform Approach
ADJUNCTIVE
MODEL
We make existing therapies more effective, maximizing the value of current standards of care and aligning with payer/provider incentives for cost savings and improved outcomes.
PLATFORM
VERSATILITY
Our artificial nucleoside technology is applicable across oncology, infectious diseases, and potentially antiviral indications, offering broad market reach and impact.
DUAL-ACTION ONCOLOGY SOLUTIONS
Our nucleosides enable both tumor visualization for precision surgery and targeted elimination of residual cancer cells, reducing recurrence and metastasis.
SYNERGY WITH
ANTIBIOTICS
Our lead product, CB-005N, restores antibiotic power against resistant and persister bacteria, tackling a $100B+ global health crisis.
The Stakes
Are High
Across the globe, drug resistance, aggressive cancers, and virus-driven diseases are straining healthcare systems.
Here’s why our work can’t wait:
39+ million
Projected deaths globally by 2050 if antibiotic resistance is unchecked
2+ million
New U.S. cancer cases and 618,000 deaths in 2025
20%
Up to 20% of all cancers worldwide are virus-driven
At the Gates of Innovation
Cerberus Biosciences
We're tackling humanity’s health threats head-on, delivering solutions where traditional therapies fall short. Here’s how we’re changing the fight against infections, cancers, and viruses:
Drug-Resistant Infections
The Crisis:
Antibiotic-resistant infections are projected to cause over 39 million deaths by 2050, with nearly 2 million lives lost annually if new solutions are not found. Hospitals face soaring costs as traditional antibiotics lose effectiveness.
Our Solution:
CB-005N, our artificial nucleoside, restores the power of existing antibiotics. Used in combination, it kills drug-resistant and persisted bacteria, preventing the spread and recurrence of deadly infections. Hospitals and payers benefit from reduced re-admissions and significant cost savings.
Hard-to-Treat Cancers
The Crisis:
Each year, over 2 million Americans are diagnosed with cancer, with more than 618,000 deaths expected in 2025. Survival rates for cancers like glioblastoma and lung cancer remain below 20% at five years. Many patients relapse after surgery due to undetected or residual tumor cells.
Our Solution:
Our nucleoside technology enables both precise tumor visualization for surgeons and targeted elimination of residual cancer cells. This dual-action approach improves surgical outcomes, reduces recurrence, and addresses urgent needs in high-mortality cancers.
Viral Diseases and
Virus-Associated Cancers
The Crisis:
Viruses are responsible for up to 20% of cancers worldwide and can trigger aggressive tumors, especially in immunocompromised populations. Standard therapies often fail to address the underlying viral drivers.
Our Solution:
Cerberus’ artificial nucleosides disrupt DNA synthesis in virus-infected cells, targeting both the virus and resulting cancer. This approach holds promise for treating virus-induced malignancies and hard-to-treat viral infections.
​Building the Future of Medicine
Side by Side with Cerberus Biosciences
Clear Value Proposition
We address multi-billion-dollar markets with a single, versatile platform.
Aligned with Market Trends
Our adjunctive, cost-saving approach fits the needs of hospitals, payers, and pharma.
Strong IP Position
Our proprietary technology is protected and differentiated.
​
Go-to-Market Pathways
Driving oncology programs toward key clinical milestones to attract partners or acquisition, while accelerating antimicrobial adoption through strategic collaborations with hospitals, insurers, and device companies
Compelling Clinical Need
We target diseases with high mortality, high cost, and few effective solutions.
Experienced Team
Led by scientific pioneers and industry veterans with a proven track record..
Meet The Founder
Anthony J. Berdis, Ph.D.
Anthony J. Berdis, Ph.D. is President and Founder of Cerberus Biosciences, LLC. Trained as a biochemist, Dr. Berdis has extensive experience in developing therapeutic and diagnostic agents in oncology and the anti-infective sectors. During his 25-year career in academia, Dr. Berdis has developed several novel anti-cancer agents against leukemia, glioblastoma multiforme, and breast cancer. Achievements include the synthesis and biological testing of over 40 different substituted indolyl-2’-deoxyribosides as next-generation DNA polymerase inhibitors. Several of these analogs also display unique therapeutic activity against drug-resistant gram-negative bacteria. His research has produced over 90 research articles and book chapters, several patents for these nucleosides as therapeutic / diagnostic agents, and over $8 million in funding from federal research grants (NIH and Department of Defense (DoD)).
Join Us at the Forefront of Therapeutic Innovation!
Partner with Cerberus Biosciences to bring life-saving solutions to market and transform the future of healthcare.
Contact our team to learn more about investment opportunities and strategic collaborations.
​
PHONE: 330.325.6395